{"id":"W4295078726","doi":"10.1200/jco.22.01549","title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":475,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; NRG Oncology; Sanofi; AstraZeneca","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Ovarian cancer; Hazard ratio; Clinical endpoint; Oncology; Placebo; Cancer; Veliparib; BRCA mutation; Clinical trial; Surgery; Poly ADP ribose polymerase; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002149116,0.0005701975,0.001385251,0.0002620814,0.0002355691,0.0007070623,0.0004890318,0.000779042,0.001186291],"category_scores_gemma":[0.001313074,0.0002025604,0.001465162,0.0003163923,0.0005277215,0.0005394711,0.000306844,0.00156211,0.0001541283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005593187,"about_ca_system_score_gemma":0.0007715046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003454811,"about_ca_topic_score_gemma":0.000981328,"domain_scores_codex":[0.9994091,0.0003608967,0.00003674633,0.00008483199,0.00004981773,0.00005870931],"domain_scores_gemma":[0.9990371,0.0002341392,0.0002946403,0.00008519957,0.00004664537,0.00030218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9367779,0.003094679,0.007288956,0.0004911647,0.001283744,0.00007674159,0.00007367761,0.0007563682,0.004392432,0.0001042085,0.0009552025,0.0447049],"study_design_scores_gemma":[0.7401344,0.215667,0.03613341,0.0001673669,0.001940881,0.000256501,0.00005593779,0.001553473,0.001514142,0.0004195086,0.002116,0.0000413679],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939658,0.004306526,0.0001749519,0.0002264346,0.00008963064,0.0002922676,0.0003196911,0.0000200264,0.0006046867],"genre_scores_gemma":[0.9952095,0.001611715,0.00042678,0.0004348788,0.0001695327,0.0007008816,0.0007786092,0.000006080503,0.000662011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002149116,"threshold_uncertainty_score":0.01136577,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0555831528157147,"score_gpt":0.3980408485949811,"score_spread":0.3424576957792664,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}